1. A compound having the general formula (I) as well as its stereoisomers and pharmaceutically acceptable salts and prodrugs； in this case, a dotted bond indicates a possible bond； R 'is H or R' is absent, with a dotted line is a bond； R1 and R4, each independently of the other, selected from the group consisting of H, halogen, lower alkyl, trifluoromethyl and trifluoromethoxy； R2 and R3 are both F, or R2 or R3 is F, then the other radical is lower alkyl or trifluoromethyl； and R5 is selected from the group consisting of halogen, lower alkyl, trifluoromethyl and trifluoromethoxy, or if the dotted line indicates a bond, then R5 may also be represented by H.2. The compound having the formula (I) according to claim 1, wherein the dashed line indicates the bond, and R1, R4 and R5 represent H, and R2 and R3 represent F.3. A compound having the formula (I) according to claim 1, wherein R1 and R4 are H, and R2, R3 and R5 are F.4. A compound having the formula (I) according to claim 1, wherein R1 and R4 are H, a R2 and R3 are F, and R5 is methyl. A compound having the formula (I) according to claim 1, wherein the compound is 6,7-difluoro-1-methyl-3,4-dihydroisoquinoline or a pharmaceutically acceptable salt thereof. A compound having the formula (I) according to claim 1, wherein the compound is 1-methyl-4,6,7-trifluoro-3,4-dihydroisoquinoline or a pharmaceutically acceptable salt thereof. A compound having the formula (I) according to claim 1, wherein the compound is 4,6,7-trifluoro-1-methyl-1,2,3,4-tetrahydroisoquinoline or a pharmaceutically acceptable salt thereof. A pharmaceutical composition containing an effective amount of one or more1. Соединение, имеющее общую формулу (I)а также его стереоизомеры и фармацевтически приемлемые соли и пролекарства；при этом пунктирной связью обозначается возможная связь；R' представляет собой Н, илиR' отсутствует, при этом пунктирной линией обозначается связь；R1 и R4, каждый независимо от другого, выбран из группы, включающей Н, галоген
